Business Context and Reporting Period
Company: A.P. Pharma, Inc. (formerly Advanced Polymer Systems, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2001
Business Overview: A specialty pharmaceutical company focused on developing proprietary polymer-based drug delivery systems (Biochronomer and Bioerodimer). The company generates revenue primarily through royalties from licensed products (Retin-A Micro, Carac) and sales of analytical standards. In July 2000, the company divested its cosmeceutical and toiletry product lines to RP Scherer, receiving $25 million upfront plus earnout rights.
Key Financial Metrics (Year Ended Dec 31, 2001)
| Metric | 2001 ($) | 2000 ($) |
|---|---|---|
| Total Revenues | 4,387,262 | 3,365,859 |
| Net Income (Loss) | (2,513,599) | 8,552,355 |
| Loss from Continuing Operations | (5,511,307) | (3,758,116) |
| Research & Development Expense | 7,348,497 | 3,713,089 |
| Cash and Cash Equivalents | 3,617,927 | 6,493,336 |
| Marketable Securities | 15,876,445 | 16,029,320 |
| Total Assets | 23,507,014 | 26,996,162 |
| Long-Term Debt | 0 | 0 |
| Working Capital | 18,074,351 | 20,087,191 |
Note: All figures in dollars. The company reported a net loss in 2001 compared to a net profit in 2000, driven by increased R&D and the absence of a large gain on discontinued operations.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 30% to $4.39 million, primarily driven by a 56% increase in royalty income ($3.25 million) due to the launch of Carac (treatment for actinic keratoses) and increased sales of Retin-A Micro.
- R&D Surge: Research and development expenses nearly doubled (98% increase) to $7.35 million. This was due to preclinical studies for the Investigational New Drug Application (IND) for APF112 (post-surgical pain treatment) and ongoing development programs.
- Discontinued Operations: The 2000 net income included an $11.1 million gain on the disposition of the cosmeceutical business. In 2001, this was replaced by a $2.89 million gain representing the first earnout payment from the sale, resulting in a net loss for the year.
- Liquidity: Cash and marketable securities decreased by approximately $3.0 million to $19.5 million, reflecting the burn rate from increased R&D activities.
- Debt: The company remains debt-free following the repayment of long-term debt in 2000 using proceeds from the asset sale.
Guidance, Outlook, and Risks
- Product Pipeline: The company initiated human clinical trials (Phase I) in January 2002 for APF112, targeting the post-surgical pain market. Phase II trials are expected later in 2002.
- Financial Outlook: Management expects R&D expenses to increase in 2002 as clinical studies progress. Royalty income is expected to increase assuming continued advertising support for Retin-A Micro and growth in Carac sales. Product sales from analytical standards are expected to remain flat.
- Liquidity Runway: Management estimates existing cash, marketable securities, and revenue streams are sufficient to fund operations for at least two years, assuming no changes to current business plans.
- Key Risks:
- Capital Needs: Future funding requirements are uncertain; the company may need to raise additional capital through collaborations or equity offerings.
- Regulatory Approval: Success depends on obtaining FDA approval for new products, a process that is uncertain, time-consuming, and costly.
- Collaborator Dependence: The company relies on partners (Johnson & Johnson, Aventis) for marketing and development of licensed products.
- Patent Protection: Risks exist regarding the validity and enforceability of patents protecting the company's technology.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $6.5 million net cash used in operating activities against the $19.5 million cash/marketable securities balance.
- Royalty Concentration: Confirm the stability of revenue streams, noting that approximately 75% of net sales in 2001 were concentrated with two customers (Johnson & Johnson and Aventis).
- APF112 Clinical Progress: Monitor the results of the Phase I and upcoming Phase II clinical trials for the post-surgical pain candidate, as this is the primary driver for future valuation.
- Earnout Payments: Track the performance of the divested cosmeceutical business to determine if further earnout payments from RP Scherer will be realized in 2002 and 2003.
- Patent Expirations: Review the expiration dates of key patents covering Retin-A Micro and Carac to assess long-term royalty revenue risks.